The Effectiveness of Cervical Pessary Compared to Cervical Cerclage With or Without Vaginal Progesterone for the Prevention of Preterm Birth in Women With a Twin Pregnancy and a Short Cervix: a Two-by-two Factorial Randomised Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 219
- 试验地点
- 1
- 主要终点
- Preterm birth <34 weeks
研究概览
简要总结
This study compares the effectiveness of cervical pessary and cervical cerclage with or without vaginal progesterone for prevention of preterm birth in women with a twin pregnancy and a cervix ≤28 mm.
Participants will be randomly assigned in a 1:1:1:1 ratio to receive cerclage, pessary, cerclage plus progesterone or pessary plus progesterone.
详细描述
This open label, multi-center, two-by-two factorial, randomised controlled trial aims to compare the effectiveness of cervical pessary to cervical cerclage and also to determine the effectiveness of vaginal progesterone for the prevention of PTB in women with a twin pregnancy and a cervix ≤28 mm.
All women with a twin pregnancy will undergo cervical length measurement and digital examination at screening. Prior to CL measurement, women will be given a short brochure outlining risk factors and available PTB prevention methods. Only women with a CL ≤28 mm will be eligible for the study. Eligible participants will be screened by midwives or gynaecologists, then participants will be provided a full participant Information Sheet, Consent Form and will be invited to a full discussion with investigators about the study. Eligible women will further undergo a speculum examination to assess the feasibility of treatment with either cerclage or cervical pessary with or without progesterone and to exclude premature rupture of the membranes (PROM), acute vaginitis and cervicitis. All eligible women will be invited to participate in the study.
After written informed consent, women will be randomly assigned in a 1:1:1:1 ratio to receive a cerclage, pessary, cerclage plus progesterone or pessary plus progesterone. Assignment to treatment allocation will be done via a web portal hosted by HOPE Research Center, Vietnam. The randomisation schedule will be computer-generated at HOPE Research Center, with a permuted random block size of 4 or 8. Blinding will not be possible due to the nature of interventions. However, neonatologists assessing the children will be unaware of treatment allocation. Apart from randomisation, patients will be followed up and treated according to local protocol.
Women allocated to a cervical cerclage will be receiving the intervention according to local protocol, within a week after randomisation. Briefly, 2 to 3 senior clinicians, who had experienced with cerclage, will perform cervical cerclage, using Mc Donald technique, under spinal anaesthesia with a single dose of prophylactic antibiotics.
For those who randomised to pessary group, a soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany), will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. The size of the pessary will be determined at the time of speculum inspection (Arabin and Alfirevic, 2013).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with a twin pregnancy (mono- and di-chorionic)
- •16 0/7 to 22 0/7 weeks of gestation
- •Maternal age ≥18 yrs
- •Cervical length ≤28 mm
- •Informed consent
- •Not participating in another preterm birth study at the same time
排除标准
- •Uterine anomalies
- •Cervical dilation with visible amniotic membranes or amniotic membranes prolapsed into the vagina
- •Twin-to-twin transfusion syndrome
- •Stillbirth or major congenital abnormalities in any of the fetus
- •Severe vaginal discharge
- •Acute vaginitis or cervicitis
- •Vaginal bleeding
- •Placental preavia
- •Vasa preavia
- •Premature rupture of membranes
- •Premature labor with/without ruptured membrane
- •Suspicion of chorioamnionitis
- •Cerclage or pessary in place or unable to undergo cervical cerclage or pessary
研究组 & 干预措施
Pessary group
A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
干预措施: Pessary (Device)
Cerclage group
Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
干预措施: Cervical cerclage (Procedure)
Pessary plus progesterone group
400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
干预措施: Pessary (Device)
Pessary plus progesterone group
400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
干预措施: Vaginal progesterone (Drug)
Cerclage plus progesterone group
400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
干预措施: Cervical cerclage (Procedure)
Cerclage plus progesterone group
400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
干预措施: Vaginal progesterone (Drug)
结局指标
主要结局
Preterm birth <34 weeks
时间窗: From date of randomisation until 33 6/7 weeks
Birth before 34 weeks' gestation
次要结局
- Iatrogenic preterm birth <34 weeks(From date of randomisation until 33 6/7 weeks)
- Mode of delivery(At birth)
- Gestational age at delivery(At birth)
- Time from randomisation to delivery(From date of randomisation until the date of delivery, assessed up to 22 weeks)
- Preterm birth <28 weeks(From date of randomisation until 27 6/7 weeks)
- Preterm birth <37 weeks(From date of randomisation until 36 6/7 weeks)
- Iatrogenic preterm birth <28 weeks(From date of randomisation until 27 6/7 weeks)
- Spontaneous preterm birth <28 weeks(From date of randomisation until 27 6/7 weeks)
- Spontaneous preterm birth <34 weeks(From date of randomisation until 33 6/7 weeks)
- Spontaneous preterm birth <37 weeks(From date of randomisation until 36 6/7 weeks)
- Onset of labor(At birth)
- Livebirth(At birth)
- Chorioamnionitis(From randomization to delivery, up to 22 weeks)
- Length of NICU admission(Up to 28 days after birth)
- Stillbirth(At birth)
- Birthweight <2500 g(At birth)
- Use of tocolytic drugs(From 24 0/7 to 33 6/7 weeks' gestation)
- Iatrogenic preterm birth <37 weeks(From date of randomisation until 36 6/7 weeks)
- Use of antenatal corticosteroids(From 24 0/7 to 33 6/7 weeks' gestation)
- Use of MgSO4 for neuroprotection(From 28 0/7 to 31 6/7 weeks' gestation)
- Maternal mortality(From randomization to delivery, up to 22 weeks)
- Birthweight(At birth)
- Congenital anomalies after randomisation(At birth)
- 5-min Apgar score(At birth)
- Necrotizing enterocolitis(Up to 28 days after birth)
- Preterm prelabour rupture of membranes(From randomization to less than 37 weeks, up to 21 weeks)
- Length of maternal admission for preterm labour(From 24 weeks to 37 week)
- Birthweight <1500 g(At birth)
- Admission to neonatal intensive care unit (NICU)(Within 7 days after birth)
- Respiratory distress syndrome(Up to 28 days after birth)
- Death before discharge(Up to 28 days after birth)
- Composite of poor perinatal outcomes(Up to 28 days after birth)
- Maternal side effects(From date of randomisation until delivery, which is up to 22 weeks)
- 5-min Apgar score <7(At birth)
- Periventricular haemorrhage II B or worse(Up to 28 days after birth)
- Proven sepsis(Up to 28 days after birth)
- Fetal death <24 weeks(From randomization to 23 6/7 weeks)
